drugset / Trial / NCT03792139

An Interaction Study of LY3200882 in Healthy Participants

NCT03792139

Phase 1 Completed 23 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelBasic science

Summary

The main purpose of this study is to evaluate the effect of itraconazole on the amount of LY3200882 in the blood stream and how long the body takes to get rid of LY3200882. The safety and tolerability of LY3200882 when given with itraconazole will be evaluated. The study is expected to last up to 19 days from the first dose to follow-up (inclusive). Screening will occur up to 28 days prior to enrollment.

Timeline

Start
2019-01-08
Primary completion
2019-02-23
Completion
2019-02-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule Oral
Subject LY3200882 Small molecule Oral

Indications

No indication recorded.